UNCY
Unicycive Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.16
−2.64%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.32
- Revenue estimate
- $902.8K
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.06
- EPS estimate
- -$0.47
- Revenue actual
- —
- Revenue estimate
- $22.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +5.1%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $25
- PT range
- $15 – $50
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026